At least 27 corporate drug development partnerships using macrocycle technologies and constrained peptide technologies have been announced since 2007, with several pharmas sampling more than one technology. Bristol-Myers Squibb Co. (NYSE:BMY) has disclosed deals for three different technologies, while Roche (SIX:ROG; OTCQX:RHHBY), Pfizer Inc. (NYSE:PFE), Novartis AG (NYSE:NVS; SIX:NOVN) and Zealand Pharma A/S (CSE:ZEAL) each have two. Source: BCIQ: BioCentury Online Intelligence; company press releases and websites

Company

Deal description

Partner

Financial terms

Date

Aileron Therapeutics Inc.

Discover, develop, and commercialize stapled peptide therapeutics

Roche (SIX:ROG; OTCQX:RHHBY)

$25M technology access fees and R&D support; $1.1B in milestones, plus royalties

Aug-2010

Ensemble Therapeutics Corp.

Use DNA-Programmed Chemistry technology to screen and identify macrocyclic Ensemblins against partners' undisclosed targets

Bristol-Myers Squibb Co. (NYSE:BMY)

$5M up front; $7.5M in research support; $30M in milestones per compound, plus royalties

Apr-2009

Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)

Undisclosed upfront payments, milestones and royalties

May-2012

Pfizer Inc. (NYSE:PFE)

Undisclosed upfront payments, research funding, milestones and royalties

Jan-2010

Lanthio Pharma B.V.

Exclusive, worldwide rights to lanthionine-Ang(1-7) peptide targeting MAS receptor in preclinical development for acute lung injury

Tarix Pharmaceuticals Ltd.

Undisclosed milestones and royalties

Feb-2012

Oncodesign S.A.

Discover and develop compounds using Nanocyclix medicinal chemistry technology; Nanocyclix is based on macrocyclic chemistry technology from Johnson & Johnson (NYSE:JNJ)

Ipsen Group (Euronext:IPN)

Undisclosed technology access fee and funding; €115M ($148.8M) in opt-in fees and milestones

Jan-2012

Sanofi (Euronext:SAN; NYSE:SNY)

€130M ($166.2M) technology access fee and milestones, plus low single-digit royalties

Sep-2012

Polyphor Ltd.

Use Macrofinder and/or Protein Epitope Mimetics (PEM) finder technologies to identify macrocyclic molecules

Allergan Inc. (NYSE:AGN)

$7M up front; $61M in milestones, plus royalties.

Oct-2008

Axxam S.p.A. (ion channel targets)

ND

Apr-2010

Axxam S.p.A. (glucagon-like peptide-1 receptor (GLP-1R) modulators)

Funding from Eurostars grant

Jul-2011

Boehringer Ingelheim GmbH

Undisclosed upfront payments, research funding, milestones and royalties

Jun-2012

Novartis AG (NYSE:NVS; SIX:NOVN)

Undisclosed upfront payments, research funding, milestones and royalties

May-2010

PeptiDream Inc.

Use cyclic peptide mRNA display technology to identify and develop hits against partners' undisclosed targets

Amgen Inc. (NASDAQ:AMGN)

ND

Oct-2010

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Nov-2010

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568)

ND

Jul-2012

MedImmune LLC/AstraZeneca plc (LSE:AZN; NYSE:AZN)

ND

Jul-2007

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)

ND

Dec-2010

Novartis AG (NYSE:NVS; SIX:NOVN)

ND

Aug-2010

Pfizer Inc. (NYSE:PFE)

ND

Dec-2010

Pepscan Therapeutics B.V.

Develop peptides using constrained peptide chemistry technology

Alvos Therapeutics Inc. (now part of Arrowhead Research Corp. (NASDAQ:ARWR))

Undisclosed research funding, milestones and royalties

Jan-2011

Bicycle Therapeutics Ltd.

ND

Nov-2009

Johnson & Johnson (NYSE:JNJ)

Undisclosed research funding, milestones and royalties

Sep-2010

Phylogica Ltd. (ASX:PYC; Xetra:PH7)

ND

May-2011

Zealand Pharma A/S (CSE:ZEAL)

Fund a portion of the work through a €860K ($1.2M) EUREKA Eurostars grant; no other details disclosed

Mar-2011

Protagonist Therapeutics Inc.

Discover and develop disulfide rich peptides (DRPs) against partners' undisclosed targets

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)

Undisclosed upfront payments, milestones and royalties

Jan-2011

Zealand Pharma A/S (CSE:ZEAL)

Undisclosed upfront payments, milestones and royalties

Jun-2012

Tranzyme Inc. (NASDAQ:TZYM)

Macrocyclic Template Chemistry (MATCH) technology to discover, develop and commercialize macrocyclic compounds

Bristol-Myers Squibb Co. (NYSE:BMY)

$10M up front; additional research funding; $80M in milestones per target program, plus tiered royalties

Dec-2009